OverviewSuggest Edit

Gracell Biotechnologies is a clinical-stage biotech company developing cell gene therapies for cancer. It focuses on leukemia, lymphoma, myeloma, and solid tumors.
TypePublic
Founded2017
HQSuzhou, CN
Websitegracellbio.com

Latest Updates

Employees (est.) (Dec 2020)202(+27%)
Share Price (Sept 2021)$13.8(+5%)
Cybersecurity ratingBMore

Key People/Management at Gracell

William Wei Cao

William Wei Cao

Founder, Chairman, and Chief Executive Officer
Martina A. Sersch

Martina A. Sersch

Chief Medical Officer
Kevin Yili Xie

Kevin Yili Xie

Chief Financial Officer
Yili Kevin Xie

Yili Kevin Xie

Chief Financial Officer
Jenny Yajin Ni

Jenny Yajin Ni

Chief Technology Officer
David Guowei Wang

David Guowei Wang

Director
Show more

Gracell Office Locations

Gracell has an office in Suzhou
Suzhou, CN (HQ)
Building 12, Block B, Phase II, Biobay Industrial Park, 218 Sangtian St., Suzhou Industrial Park
Show all (2)

Gracell Financials and Metrics

Gracell Revenue

CNY

Net income (FY, 2019)

(138.7m)

EBIT (FY, 2019)

(146.6m)

Market capitalization (17-Sept-2021)

924.2m

Closing stock price (17-Sept-2021)

13.8

Cash (30-Sept-2020)

156.8m

EV

832.3m
Gracell's current market capitalization is $924.2 m.
CNYFY, 2018FY, 2019

General and administrative expense

10.3m27.4m

R&D expense

52.2m119.2m

Operating expense total

62.5m146.6m

EBIT

(62.5m)(146.6m)
Annual
CNYFY, 2018FY, 2019

Cash

11.9m312.1m

Prepaid Expenses

4.5m5.4m

Current Assets

128.0m340.4m

PP&E

16.3m48.3m
Quarterly
CNYQ3, 2020

Cash

156.8m

Prepaid Expenses

3.8m

Current Assets

215.7m

PP&E

112.1m
Annual
CNYFY, 2018FY, 2019

Net Income

(60.8m)(138.7m)

Depreciation and Amortization

3.0m5.1m

Cash From Operating Activities

(61.9m)(135.4m)

Purchases of PP&E

(11.4m)(56.4m)
Quarterly
USDQ3, 2019Q3, 2020

Net Income

(95.9m)(128.3m)

Depreciation and Amortization

3.8m12.2m

Cash From Operating Activities

(102.6m)(134.2m)

Purchases of PP&E

(46.2m)(65.3m)
CNYFY, 2018

Financial Leverage

-1.8 x
Show all financial metrics

Gracell Operating Metrics

Q3, 2020

Preclinical Phase Products

1

Phase I Trials Products

4
Show all operating metrics

Gracell Acquisitions / Subsidiaries

Company NameDateDeal Size
Gracell Biomedicine (Shanghai) Co., Ltd.
Gracell Biopharmaceuticals, Inc.
Gracell Bioscience (Shanghai) Co., Ltd.
Gracell Biotechnologies (HK) Limited
Gracell Biotechnologies Holdings Limited

Gracell Cybersecurity Score

Cybersecurity ratingPremium dataset

B

86/100

SecurityScorecard logo

Gracell Online and Social Media Presence

Embed Graph

Gracell News and Updates

Gracell Biotechnologies to Participate in Upcoming Virtual Investor Conferences in September

SUZHOU, China and PALO ALTO, Calif., Aug. 26, 2021 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) (“Gracell”), a global clinical-stage biopharmaceutical company dedicated to discovering and developing highly efficacious and affordable cell therapies for the treatment of cancer, to…

Gracell Biotechnologies Reports Second Quarter 2021 Unaudited Financial Results and Provides Corporate Update

SUZHOU, China and PALO ALTO, Calif., Aug. 17, 2021 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) (“Gracell”), a global clinical-stage biopharmaceutical company dedicated to discovering and developing highly efficacious and affordable cell therapies for the treatment of cancer, to…

Gracell Biotechnologies to Report Second Quarter Financial Results on Tuesday, August 17, 2021

SUZHOU, China and PALO ALTO, Calif., Aug. 03, 2021 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) (“Gracell”), a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious and affordable cell therapies for the treatment of cancer, today announced th…

Gracell Biotechnologies to Participate in Fireside Chat at the BTIG Virtual Biotechnology Conference

SUZHOU, China and PALO ALTO, Calif., July 26, 2021 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) (“Gracell”), a global clinical-stage biopharmaceutical company dedicated to discovering and developing highly efficacious and affordable cell therapies for the treatment of cancer, to…

Gracell Biotechnologies Reschedules Clinical Update Conference Call and Webcast to June 14, 2021

SUZHOU, China and PALO ALTO, Calif., June 02, 2021 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) (“Gracell”), a global clinical-stage biopharmaceutical company dedicated to discovering and developing highly efficacious and affordable cell therapies for the treatment of cancer, to…

Gracell Biotechnologies to Host Clinical Update Conference Call and Webcast on June 4, 2021 at 11:00am EDT

SUZHOU, China and PALO ALTO, Calif., May 21, 2021 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) (“Gracell”), a global clinical-stage biopharmaceutical company dedicated to discovering and developing highly efficacious and affordable cell therapies for the treatment of cancer, tod…
Show more

Gracell Frequently Asked Questions

  • When was Gracell founded?

    Gracell was founded in 2017.

  • Who are Gracell key executives?

    Gracell's key executives are William Wei Cao, Martina A. Sersch and Kevin Yili Xie.

  • How many employees does Gracell have?

    Gracell has 202 employees.

  • Who are Gracell competitors?

    Competitors of Gracell include Kyowa Kirin, Takeda Oncology and Celltrion Healthcare.

  • Where is Gracell headquarters?

    Gracell headquarters is located at Building 12, Block B, Phase II, Biobay Industrial Park, 218 Sangtian St., Suzhou Industrial Park, Suzhou.

  • Where are Gracell offices?

    Gracell has an office in Suzhou.

  • How many offices does Gracell have?

    Gracell has 2 offices.